Nebenwirkungen · Soliris
Soliris 300 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-118092 · Präparat HOS-094753
Included Studies: Asthma (C07-002), aHUS(C08-002, C08-003, C10-003, C10-004), Dermatomyositis (C99-006), refractory gMG (C08-001, ECU-MG-301, ECU-MG-302, ECU-MG-303), Neuromyelitis Optica Spectrum Disorder (ECU-NMO-301, ECU-NMO-302), IMG (C99-004, E99-004), PNH (C02-001, C04-001, C04-002, C06-002, C07- 001, E02-001, E05-001, E07-001, M07-005, X03-001, X03-001A), Psoriasis (C99-007), RA (C01-004, C97-001, C99-001, E01-004, E99-001), STEC-HUS (C11-001), SLE (C97-002). MedDRA version 26.1. *See paragraph Description of selected adverse reactions. a Abscess includes the following group of PTs: Abscess limb, Colonic abscess, Renal abscess, Subcutaneous abscess, Tooth abscess, Liver abscess, Perirectal abscess, Rectal abscess. b Meningococcal infection includes the following group of PTs: Meningococcal infection, Meningococcal sepsis, Meningitis meningococcal. c ADRs identified in postmarketing reports d Frequency cannot be estimated from the available postmarketing data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-18T16:51:00Z · SHA-256 b254b201b05164093aea1fcfce38f32747566e49a27d2950669846f9482cafae · Passage 003dce9e59aed091efa0cba0e289bdbb34ad693cdd75439cc3970cda29ccfed5 · Zeichen 7647–8635 im Abschnitt